Catalyst + talent = Catalent. At least, that's the brand Catalent Pharma Solutions is using to try to ensure its customers' success. The company provides contract development and manufacturing of oral (soft and hardshell capsules), topical (ointment applicators), sterile (syringes), and inhaled (nasal sprays) drug delivery products to pharmaceutical and biotechnology companies in some 100 countries. Catalent also provides packaging services, using bottles, pouches, and strips used to hold tablet, powder, and liquid medicines. Catalent operates 30 facilities worldwide. The company is owned by The Blackstone Group.
Sales and Marketing
Catalent serves a range of generic and prescription pharmaceutical, biotechnology, and consumer health care companies. Key customers for the firm's outsourced development, manufacturing, packaging, and regulatory consulting services include Pfizer, Johnson & Johnson, and Genentech.
Europe and the US represent Catalent's largest market segments, together accounting for 84% of sales in 2012.
The company's revenues grew by 11% in 2012 thanks to increased demand within the Development & Clinical Services and the Oral Technologies segments, partially offset by decreases within its Medication Delivery Solutions segment. The Oral Technologies increase was a result of growth in demand for prescription and consumer health softgels within multiple geographies, as well as an increase in demand for controlled release products within North America and Europe. The Development & Clinical Services volume increase was primarily related to a growth in demand for clinical and analytical services within North America and Europe, as well as due to the acquisition of Aptuit's clinical trials supplies business.
The company's net loss decreased by 25% in 2012 thanks to higher revenues and an increase in other income primarily because while non-cash unrealized foreign currency transaction losses were recognized in 2011, no such losses were recorded in 2012.
Catalent's business strategy focuses on growing its businesses in development solutions and advanced delivery technologies, clinical trial supplies, and advanced blow/fill/seal aseptic delivery technology for respiratory, ophthalmic and other products. It is also working to offer integrated solutions for developing and supplying injectable biologics and complex pharmaceutical products.
Based on this strategy, the company sold its US commercial packing operations to an affiliate of Frazier Healthcare in 2012. The company's commercial packaging activities outside North America were not affected.
In 2012 Catalent strengthened its contract research services for drug companies by acquiring Aptuit's clinical trial supplies business for $410 million.
Other growth plans include adding new service offerings and expanding into new market segments. The company is also looking to add new partnerships that will allow for increased participation in licensing and commercialization profit-sharing opportunities. In addition, the company is capitalizing on increased manufacturing capacity in its oral technologies and sterile technologies businesses, where it invested in growing market segments such as prefilled syringes and oral dose products.
In 2012 the company entered into a series of sales agreements which included a commercial cell line sales agreement with CEVEC Pharmaceuticals for recombinant human alpha-1 antitrypsin, and a supply agreement with VIVUS to supply Qsymia capsules, a proprietary combination phentermine and extended-release topiramate.
Catalent was formed in 2007 when Blackstone acquired Cardinal Health's pharmaceutical technologies segment for $3.3 billion.